Our previous studies have shown that the Se/FO combination treatment increases the therapeutic efficacy of anti-cancer agents against breast cancer via the dose-dependent downregulation of TGF-β/TβR-2, AXL/Gas6, and β-catenin signaling [27]. The gene discussed is AXL; the disease is cancer.